Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,exchange,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,marketState,market,shortName,exchangeDataDelayedBy,esgPopulated,tradeable,priceHint,regularMarketChangePercent,regularMarketDayRange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,VX1.DE,7794238000,258866000,,,-44255000,,66924000,194669000,158308000,-36361000,-36361000,,-15478000,,,,-111179000,1793370000,1829731000,1635062000,-7894000,,66924000,66924000,400000000,7640233000,3025290000,9196396000,226358000,12221686000,2591000,16935000,1578731000,294993000,1002158000,-25159000,1003107000,6063678000,1836448000,952808000,-25159000,1338107000,8457514000,20800000,644315000,929142000,321620000,127534000,-14804000,-13701000,-79641000,-2309000,33550000,-178575000,37935000,-241839000,-3524000,4019000,-199767000,31238000,-15000000,-24707000,52525000,1448000,-133471000,-49837000,6621066000,en-US,US,EQUITY,False,Delayed Quote,GER,EUR,167.42,1630569057,0.41999817,167.42,167.42,167.42,5,167.0,165.64,166.58,finmb_36235,XETRA,Vertex Pharmaceuticals Incorporated,USD,498,212,15.2400055,0.10014461,152.18 - 241.7,-74.28,-0.30732313,152.18,241.7,1619726400,1635332340,1635768000,19.048811,REGULAR,de_market,"VERTEX PHARMAC.  DL-,01",0,False,False,2,0.2514959,167.42 - 167.42,8.789,34.696,168.67429,-1.2542877,-0.0074361525,173.29028,-5.870285,-0.033875443,43707166720,4.8253403,15,Europe/Berlin,CEST,7200000,0.63,,,241.7,152.18,168.67,173.29,498,212,258.87M,,258.85M,0.13%,91.67%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",29.80%,33.93%,12.63%,23.83%,6.68B,25.76,17.60%,3.64B,2.38B,1.99B,8.79,-92.00%,6.71B,25.86,893.85M,9.72,4.61,34.70,2.12B,1.1B,Value,02210,Healthcare,3400,7,6,"Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",Boston,617 341 6100,MA,6,1609372800,1625097600,7,United States,http://www.vrtx.com,86400,7,50 Northern Avenue,Biotechnology
t-1,VX1.DE,7578096000,258866000,,,820960000,,653138000,192077000,1076003000,883926000,883926000,,-15678000,,,,167822000,1724305000,840379000,648302000,-62966000,,653138000,653138000,400000000,7499161000,3134805000,8980254000,284174000,12115059000,2588000,15616000,1511807000,291958000,1002158000,-33302000,844352000,6304330000,1944050000,815890000,-33302000,1308442000,8539307000,20800000,619638000,977551000,298863000,127839000,-3383000,-10644000,-74309000,-8601000,-518654000,147941000,15559000,324062000,-527092000,-4030000,921055000,28834000,-15000000,-22785000,-98373000,1480000,222944000,-70926000,6595257000,en-US,US,EQUITY,False,Delayed Quote,GER,EUR,167.42,1630569057,0.41999817,167.42,167.42,167.42,5,167.0,165.64,166.58,finmb_36235,XETRA,Vertex Pharmaceuticals Incorporated,USD,498,212,15.2400055,0.10014461,152.18 - 241.7,-74.28,-0.30732313,152.18,241.7,1619726400,1635332340,1635768000,19.048811,REGULAR,de_market,"VERTEX PHARMAC.  DL-,01",0,False,False,2,0.2514959,167.42 - 167.42,8.789,34.696,168.67429,-1.2542877,-0.0074361525,173.29028,-5.870285,-0.033875443,43707166720,4.8253403,15,Europe/Berlin,CEST,7200000,0.63,,,241.7,152.18,168.67,173.29,498,212,258.87M,,258.85M,0.13%,91.67%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",29.80%,33.93%,12.63%,23.83%,6.68B,25.76,17.60%,3.64B,2.38B,1.99B,8.79,-92.00%,6.71B,25.86,893.85M,9.72,4.61,34.70,2.12B,1.1B,Value,02210,Healthcare,3400,7,6,"Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",Boston,617 341 6100,MA,6,1609372800,1625097600,7,United States,http://www.vrtx.com,86400,7,50 Northern Avenue,Biotechnology
t-2,VX1.DE,7284657000,258866000,,,888623000,,604190000,211843000,958135000,746292000,746292000,,-16288000,,,,284433000,1627820000,881528000,669685000,142331000,,604190000,604190000,400000000,7894027000,3064993000,8686815000,368641000,11751808000,2599000,658000,858669000,297955000,1002158000,-68480000,911373000,5988187000,1877533000,882779000,-68480000,1284098000,8133379000,20800000,670710000,885352000,280777000,155139000,291436000,35123000,243747000,-3547000,-125192000,-232924000,30092000,627860000,-151599000,17773000,491532000,29355000,-15000000,-37107000,-72253000,-138000,165148000,-47689000,6255846000,en-US,US,EQUITY,False,Delayed Quote,GER,EUR,167.42,1630569057,0.41999817,167.42,167.42,167.42,5,167.0,165.64,166.58,finmb_36235,XETRA,Vertex Pharmaceuticals Incorporated,USD,498,212,15.2400055,0.10014461,152.18 - 241.7,-74.28,-0.30732313,152.18,241.7,1619726400,1635332340,1635768000,19.048811,REGULAR,de_market,"VERTEX PHARMAC.  DL-,01",0,False,False,2,0.2514959,167.42 - 167.42,8.789,34.696,168.67429,-1.2542877,-0.0074361525,173.29028,-5.870285,-0.033875443,43707166720,4.8253403,15,Europe/Berlin,CEST,7200000,0.63,,,241.7,152.18,168.67,173.29,498,212,258.87M,,258.85M,0.13%,91.67%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",29.80%,33.93%,12.63%,23.83%,6.68B,25.76,17.60%,3.64B,2.38B,1.99B,8.79,-92.00%,6.71B,25.86,893.85M,9.72,4.61,34.70,2.12B,1.1B,Value,02210,Healthcare,3400,7,6,"Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",Boston,617 341 6100,MA,6,1609372800,1625097600,7,United States,http://www.vrtx.com,86400,7,50 Northern Avenue,Biotechnology
t-3,VX1.DE,6731315000,258866000,,,745871000,,667434000,184551000,858592000,674041000,674041000,,-13856000,,,,78437000,1538271000,864230000,679679000,71830000,,667434000,667434000,400000000,7917375000,3168160000,8133473000,192541000,11301633000,2601000,3571000,254479000,617620000,1002158000,-40982000,1499306000,5358087000,2004026000,1147816000,-40982000,920913000,7458456000,20800000,792971000,791917000,245460000,107786000,-73142000,1456000,-247937000,-8787000,-140684000,111989000,21796000,525285000,-148535000,6158000,907748000,26642000,-15000000,-30521000,12948000,-5158000,117800000,-174795000,5454430000,en-US,US,EQUITY,False,Delayed Quote,GER,EUR,167.42,1630569057,0.41999817,167.42,167.42,167.42,5,167.0,165.64,166.58,finmb_36235,XETRA,Vertex Pharmaceuticals Incorporated,USD,498,212,15.2400055,0.10014461,152.18 - 241.7,-74.28,-0.30732313,152.18,241.7,1619726400,1635332340,1635768000,19.048811,REGULAR,de_market,"VERTEX PHARMAC.  DL-,01",0,False,False,2,0.2514959,167.42 - 167.42,8.789,34.696,168.67429,-1.2542877,-0.0074361525,173.29028,-5.870285,-0.033875443,43707166720,4.8253403,15,Europe/Berlin,CEST,7200000,0.63,,,241.7,152.18,168.67,173.29,498,212,258.87M,,258.85M,0.13%,91.67%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",29.80%,33.93%,12.63%,23.83%,6.68B,25.76,17.60%,3.64B,2.38B,1.99B,8.79,-92.00%,6.71B,25.86,893.85M,9.72,4.61,34.70,2.12B,1.1B,Value,02210,Healthcare,3400,7,6,"Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",Boston,617 341 6100,MA,6,1609372800,1625097600,7,United States,http://www.vrtx.com,86400,7,50 Northern Avenue,Biotechnology
